Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome

Clinical Endocrinology

Volumn 48, Issue 6, 1998, Pages 769-775

  Grugni, G ^a   Guzzaloni, G ^a   Moro, D ^a   Bettio, D ^a   De Medici, C ^a   Morabito, F ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CLONIDINE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; LEVODOPA; PYRIDOSTIGMINE;

ADOLESCENT; ADULT; ARTICLE; BONE MATURATION; CLINICAL ARTICLE; FEMALE; GROWTH HORMONE RELEASE; HUMAN; INSULIN TOLERANCE TEST; MALE; OBESITY; PATHOGENESIS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PUBERTY; RADIOIMMUNOASSAY;

ADOLESCENT; ADULT; CHILD; CHOLINESTERASE INHIBITORS; FEMALE; GROWTH DISORDERS; GROWTH HORMONE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; OBESITY; PRADER-WILLI SYNDROME; PYRIDOSTIGMINE BROMIDE;

EID: 0031838835     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1998.00435.x     Document Type: Article

References (49)

1. Angulo, M., Castro-Magana, M. & Uy, J. (1991) Pituitary evaluation and growth hormone treatment in Prader-Willi syndrome. Journal of Pediatric Endocrinology, 4, 167-173.
2. Angulo, M., Castro-Magana, M., Uy, J. & Rosenfeld, W. (1992) Growth Hormone evaluation and treatment in Prader-Willi Syndrome. In Prader-Willi Syndrome and other Chromosome 15q Deletion Disorders (ed. S.B. Cassidy), vol. 61, NATO ASI series, series H Cell Biology, Springer-Verlag, Berlin, pp. 171-174.
3. Angulo, M., Castro-Magana, M., Mazur, B., Canas, J.A., Vitollo, P.M. & Sarrantonio, M. (1996) Growth Hormone secretion and effects of Growth Hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome. Journal of Pediatric Endocrinology and Metabolism, 9, 393-400.
4. Beccaria, L., Benzi, F., Sanzari, A., Bosio, L., Brambilla, P. & Chiumello, G. (1996) Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome. Journal of Endocrinological Investigation, 19, 687-692.
5. Bray, G.A., Dahms, W.T., Swerdloff, R.S., Fiser, R.H., Atkinson, R.L. & Carrel, R.E. (1983) The Prader-Willi syndrome. Medicine, 62, 59-80.
6. Butler, M.G. & Meaney, F.J. (1991) Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics, 88, 853-860.
7. Calisti, L., Giannessi, N., Cesaretti, G. & Saggese, G. (1991) Endocrine study in Prader-Willi syndrome. Report of 5 cases. Minerva Pediatrica, 43, 587-593.
8. Cappa, M., Loche, S., Salvatori, R., Faedda, A., Borrelli, P., Cella, S.G., Pintor, C. & Muller, E.E. (1991) The growth hormone response to pyridostigmine plus growth hormone releasing hormone is not influenced by pubertal maturation. Journal of Endocrinological Investigation, 14, 41-45.
9. Cappa, M., Grossi, A., Borrelli, P., Ghigo, E., Bellone, J., Benedetti, S., Carta, D. & Loche, S. (1993) Growth Hormone (GH) response to combined pyridostigmine and GH-Releasing Hormone administration in patients with Prader-Labhardt-Willi syndrome. Hormone Reseach, 39, 51-55.
10. Coplin, S.S., Hine, J. & Gormican, A. (1976) Out-patient dietary management in the Prader-Willi syndrome. Journal of American Dietetic Association, 68, 330-334.
11. Cordido, F., Casanueva, F.F. & Dieguez, C. (1989) Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity. Journal of Clinical Endocrinology and Metabolosm, 68, 290-293.
12. Costeff, H., Holm, V.A., Ruvalcaba, R. & Shaver, J. (1990) Growth Hormone secretion in Prader-Willi syndrome. Acta Paediatrica Scandinavica, 79, 1059-1062.
13. Dammacco, F., Boghen, M.F., Camanni, F., Cappa, M., Ferrari, C., Ghigo, E., Giordano, G., Loche, S., Minuto, F., Mucci, M. & Muller, E.E., The Italian Collaborative Group of Neuroendocrinology (1993) Somatropic function in short stature: evaluation by integrated auxological and hormonal indices in 214 children. Journal of Clinical Endocrinology and Metabolism, 77, 68-72.
14. Devesa, J., Lima, L., Nois, N., Lechjga, M.J., Arce, V. & Tresguerres, J.A.F. (1989) Reasons for the variability in the growth hormone (GH) responses to GHRH challenge: The endogenous hypothalamic-somatotroph rhythm (HSR). Clinical Endocrinology, 30, 367-377.
15. Donaldson, M.D.C., Chu, C.E., Cooke, A., Wilson, A., Greene, S.A. & Stephenson, J.B.P. (1994) The Prader-Willi syndrome. Archives of Disease in Childhood, 70, 58-63.
16. Ghigo, E., Mazza, E., Corrias, A., Imperiale, E., Goffi, S., Arvat, E., Bellone, J., De Sanctis, C., Muller, E.E. & Camanni, F. (1989) Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children. Metabolism, 38, 631-633.
17. Ghigo, E., Imperiale, E., Boffano, G.M., Mazza, E., Bellone, J., Arvat, E., Procopio, M., Goffi, S., Barreca, A., Chiabotto, P., Lala, R., De Sanctis, C., Boghen, M.F., Muller, E.E. & Camanni, F. (1990) A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: Combined administration of pyridostigmine and growth hormone-releasing hormone. Journal of Endocrinological Investigation, 13, 307-316.
18. Ghigo, E., Procopio, M., Boffano, G.M., Arvat, E., Valente, F., Maccario, M., Mazza, E. & Camanni, F. (1992) Arginine potentiates but does not restore the blunted GH response to GHRH in obesity. Metabolism, 41, 560-563.
19. Glass, A.R. (1989) Endocrine aspects of obesity. Medical Clinics of North America, 73, 139-160.
20. Greenswag, L.R. (1987) Adults with Prader-Willi syndrome: a survey of 232 cases. Developmental Medicine and Child Neurology, 29, 145-152.
21. Hochberg, Z., Hertz, P., Colin, V., Ish-Shalom, S., Yeshurun, D., Youdim, M.B.H. & Amit, T. (1992) The distal axis of growth hormone (GH) in nutritional disorders: GH-binding protein, insulin-like growth factor-I (IGF-I), and IGF-I receptors in obesity and anorexia nervosa. Metabolism, 41, 106-112.
22. Holm, V.A. & Nugent, J.K. (1982) Growth in the Prader-Willi syndrome. Birth Defects, 18, 93-100.
23. Holm, V.A., Cassidy, S.B., Butler, M.G., Hanchett, J.M., Greenswag, L.R., Whitman, B.Y. & Greenberg, F. (1993) Prader-Willi Syndrome: Consensus Diagnostic Criteria. Pediatrics, 91, 398-402.
24. Joint FAO/WHO/UNU (1985) Expert consultation. Energy and protein requirements. WHO Technical Report Series, no. 724. WHO, Geneva.
25. Juul, A., Bang, P., Hertel, N.T., Main, K., Dalgaard, P., Jorgensen, K., Muller, J., Hall, K. & Skakkebaek, N.E. (1994) Serum insulin-like growth factor-1 in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. Journal of Clinical Endocrinology and Metabolism, 78, 744-752.
26. Lee, E.J., Kim, K.R., Lee, K.M., Lim, S.K., Lee, H.C., Lee, J.H., Lee, D.J. & Huh, K.B. (1994) Reduced growth hormone response to I-dopa and pyridostigmine in obesity. International Journal of Obesity, 18, 465-468.
27. Lee, P.D.K., Wilson, D.M., Rountree, L., Hintz, R.L. & Rosenfeld, R.G. (1987) Linear growth response to exogenous growth hormone in Prader-Willi Syndrome. American Journal of Medical Genetics, 28, 865-871.
28. Loche, S., Pintor, C., Cappa, M., Ghigo, E., Puggioni, R., Locatelli, V. & Muller, E.E. (1989) Pyridostigmine counteracts the blunted growth hormone response to growth hormone releasing hormone of obese children. Acta Endocrinologica (Copenhagen), 120, 624-628.
29. Low, L.C.K., Wang, C., Cheung, P.T., Ho, P., Lam, K.S.L., Young, R.T.T., Yeung, C.Y. & Ling, N. (1988) Long-term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. Journal of Clinical Endocrinology and Metabolism, 66, 611-617.
30. Marshall, W.A. & Tanner, J.M. (1969) Variation in the pattern of pubertal changes in girls. Archives of Disease in Childhood, 44, 291-303.
31. Marshall, W.A. & Tanner, J.M. (1970) Variation in the pattern of pubertal changes in boys. Archives of Disease in Childhood, 45, 13-23.
32. Mascari, M.J., Gottlieb, W., Rogan, P.K., Butler, M.G., Waller, D.A., Armour, J.A.L., Jeffreys, A.J., Ladda, R.L. & Nicholls, R.D. (1992) The frequency of uniparental disomy in Prader-Willi syndrome. New England Journal of Medicine, 326, 1599-1607.
33. Massara, F., Ghigo, E., Molinatti, P., Mazza, E., Locatelli, V. & Muller, E.E. (1986) Potentiation of cholinergic tone by pyridostigmine bromide re-instates and potentiates the growth hormone responsiveness to intermittent administration of growth hormone releasing factor in man. Acta Endocrinologica (Copenhagen), 113, 12-16.
34. Michel, G., Chaussain, J.L. & Job, J.C. (1976) Les explorations endocriniennes dans le syndrome de Prader, Labhardt et Willi. Archives Françaises de Pédiatrie, 33, 466-467.
35. Minuto, F., Barreca, A., Del Monte, P., Fortini, P., Resentini, M., Morabito, F. & Giordano, G. (1988) Spontaneous growth hormone and somatomedin-c/insulin-like growth factor-1 secretion in obese subjects during puberty. Journal of Endocrinological Investigation, 11, 489-495.
36. Parra, A., Cervantes, C. & Schultz, R.B. (1973) Immunoreactive insulin and growth hormone responses in patients with Prader-Willi syndrome. Journal of Pediatrics, 83, 587-593.
37. Procopio, M., Ghigo, E., Maccario, M., Boffano, G.M., Oleandri, S.E., Arvat, E., Bellone, J., Mucci, M., Boghen, M.F. & Camanni, F. (1992) Effects of arginine, repeated growth hormone(GH)-releasing hormone (GHRH) administration and fasting on the acute GH response to GHRH in obesity (abstract). Journal of Endocrinological Investigation, 15(suppl 4), 47.
38. Ritzen, M.E., Bolme, P. & Hall, K. (1992) Endocrine physiology and therapy in Prader-Willi syndrome. In Prader-Willi Syndrome and other Chromosome 15q Deletion Disorders (ed. S. B. Cassidy), vol. 61, NATO ASI series, series H Cell Biology, Springer-Verlag, Berlin, pp. 153-169.
39. Rolland-Cachera, M.F., Sempè, M., Guilloud-Bataille, M., Patois, E., Pequinot-Gugenbuhl, F. & Fautrad, V. (1982) Adiposity indices in children. American Journal of Clinical Nutrition, 36, 178-184.
40. Ross, R.J.M., Tsagarakis, S., Grossman, A., Preece, M.A., Rodda, C., Davies, P.S.W., Rees, L.H. & Savage, M.O. (1987) Treatment of growth hormone deficiency with growth-hormone-releasing hormone. Lancet, i, 5-8.
41. Ruvalcaba, R.H.A. & Holm, V.A. (1993) Effects of growth hormone in Prader-Willi syndrome. Clinical Pediatrics, 32, 292-295.
42. Schoeller, D.A., Levitsky, L.L., Bandini, L.G., Dietz, W.W. & Walczak, A. (1988) Energy expenditure and body composition in Prader-Willi syndrome. Metabolism, 37, 115-120.
43. Spiliotis, B.E., August, G.P., Hung, W., Mendelson, W. & Bercu, B.B. (1984) Growth hormone neurosecretory dysfunction: a treatable cause of short stature. Journal of the American Medical Association, 251, 2223-2320.
44. Tanner, J.M., Whitehouse, R.H. & Takaishi, M. (1966) Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. Archives of Disease in Childhood, 41, 613-635.
45. Vanderschueren-Lodeweyckx, M. (1993) The effect of simple obesity on growth and Growth Hormone. Hormone Research, 40, 23-30.
46. Veldhuis, J.D., Iranmanesh, A., Ho, K.K.Y., Water, M.J., Johnson, M.L. & Lizarralde, G. (1991) Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. Journal of Clinical Endocrinology and Metabolism, 72, 51-59.
47. Weninger, M., Frisch, H., Widhalm, K. & Schernthaner, G. (1983) Endokrine Untersuchungen bei Prader-Labhart-Willi Syndrome: Pubertatseintritt bei einem 19 Jahr alten Knaben nach Langzeitverabreichung eines LHRH-analogens. Experimental Clinical Endocrinology, 82, 8-14.
48. Wu, R.H., Louis, Y.S., Rubin, K., Cassidy, S.B., Thorpy, M.J. & Saenger, P. (1988) Growth Hormone therapy in Prader-Willi syndrome. Pediatric Research, 23, 207A.
49. Yamamoto, H., Sohmiya, M., Oka, N. & Kato, Y. (1991) Effects of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta Endocrinologica (Copenh), 124, 497-500.